X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

TRVN

Closed

Trevena Inc

2.
0 (0.00%)
Last Update: 17 Oct 2024 22:41:00
Yesterday: 2.34
Day's Range: 1.9 - 2.4
Send
When Written:
 
0.671
Trevena Inc. is a biopharmaceutical company that develops and commercializes innovative therapies for patients affected by central nervous system (CNS) disorders. The company's lead product candidate is OLINVO (oliceridine), a new chemical entity for the management of moderate to severe acute pain in adults. OLINVO is a G protein-biased mu-opioid receptor agonist designed to provide effective pain relief with fewer side effects compared to traditional opioids.

Trevena was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania. The company has a team of experienced scientists and researchers who are dedicated to discovering and developing novel therapeutics for CNS disorders. In addition to OLINVO, Trevena has a pipeline of other product candidates in various stages of development, including TRV250, a delta-opioid receptor agonist for the treatment of acute migraine, and TRV734, a novel G protein-biased ligand of the mu-opioid receptor for the treatment of CNS disorders.

Trevena is committed to advancing the science of pain management and improving the lives of patients suffering from acute and chronic pain. The company's innovative approach to drug discovery and development has earned it recognition as a leader in the field of CNS therapeutics.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:3.144.40.182
X